Stefanie Sarantopoulos

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:3865-74. 2009
  2. pmc High levels of B-cell activating factor in patients with active chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncolog, Dana Farber Cancer Institute and Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:6107-14. 2007
  3. pmc Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation
    Fabrice Porcheray
    Department of Surgery, Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Transplantation 92:359-65. 2011
  4. pmc Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease
    Caron A Jacobson
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    Biol Blood Marrow Transplant 20:668-75. 2014
  5. pmc Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes
    Yishai Ofran
    Division of Hematologic Malignancies, Cancer Vaccine Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 16:1642-51. 2010
  6. pmc Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 122:1510-7. 2013
  7. pmc Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
    Vincent T Ho
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:15825-30. 2009

Detail Information

Publications7

  1. pmc Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:3865-74. 2009
    ..These studies delineate specific abnormalities of B-cell homeostasis in patients with cGVHD and suggest that BAFF targeting agents may be useful in this disease...
  2. pmc High levels of B-cell activating factor in patients with active chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncolog, Dana Farber Cancer Institute and Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:6107-14. 2007
    ..Thus, we tested whether BAFF correlated with chronic GVHD disease activity and time of onset after allogeneic hematopoietic stem cell transplantation (HSCT)...
  3. pmc Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation
    Fabrice Porcheray
    Department of Surgery, Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Transplantation 92:359-65. 2011
    ..Here, we examined T- and B-cell responses to DBY antigen in a male patient who received hematopoietic stem cells from a human leukocyte antigen-identical female sibling...
  4. pmc Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease
    Caron A Jacobson
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    Biol Blood Marrow Transplant 20:668-75. 2014
    ..Taken together, our results are important for interpreting BAFF measurements in cGVHD biomarker studies. ..
  5. pmc Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes
    Yishai Ofran
    Division of Hematologic Malignancies, Cancer Vaccine Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 16:1642-51. 2010
    ..Because relatively few mHAs are known, we developed a new approach to predict and subsequently validate candidate mHA...
  6. pmc Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 122:1510-7. 2013
    ..039). Rituximab can prevent systemic corticosteroid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be tested in a prospective randomized trial...
  7. pmc Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
    Vincent T Ho
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:15825-30. 2009
    ....